Followers | 6 |
Posts | 2155 |
Boards Moderated | 0 |
Alias Born | 11/26/2014 |
Tuesday, October 17, 2017 11:59:32 AM
How can IPCI management justify these things:
1. Regabatin not moving forward at all. Pfizer just got their drug approved and IPCI has not done anything. Nothing.... But keep pumping it as part of pipeline... When it is NOTHING! The only saving grace is Pfizer did not get approval for Fybromyalgia.
2. Inability to partner/monetize approved products. Yet take $1M bonus' for each one. Sad... Sad... Sad... Probably bought a new Lambo with the money.
3. Inability to partner pipeline.
4. ANDA approvals that were not approved because the FDA issued CRLs or asked for more info. Truth be told, these non approvals were at least 50% IPCI's fault for incomplete/poor applications. And IPCI's slow response to the FDA's new requests.
5. The Odidi's draw about $1.5M in salary annually. That is more than 10% of IPCI's total yearly expenses. How can they justify these large payouts when the company has floundered for many years... How much is $1.5M as a % of IPCI's pathetic market cap? Answer: way too much!
Now you know I have supported the same people I am bashing now. But enough is enough and something needs to be done. Wake up Odidi!
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
- L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - IPCI • PR Newswire (Canada) • 06/08/2023 05:30:00 PM
- Canadian Investment Regulatory Organization Trade Resumption - IPCI • PR Newswire (Canada) • 06/08/2023 05:28:00 PM
- Intellipharmaceutics Announces Fiscal Year 2022 and First Quarter 2023 Results • PR Newswire (Canada) • 06/06/2023 10:00:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM